AR
ARDX.US Ardelyx Inc
- Market cap
- USD 777M
- P/E
- -
- P/B
- 4.77x
- ROE
- -44.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARDX.US undervalued?
Graham numberThe Graham number of Ardelyx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ardelyx Inc fundamental analysis
No fundamental analysis for Ardelyx Inc yet.
Ardelyx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name…
Full company profileArdelyx Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ardelyx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 24.0M | 42.0M | 2.61M | 5.28M | 7.57M | 10.1M | 52.2M | 124M | 334M | 407M | 457M |
| Gross Profit | 22.7M | 33.6M | 2.14M | 4.68M | 7.43M | 9.10M | 48.0M | 107M | 283M | 365M | 437M |
| Operating Income | -113M | -65.1M | -90.9M | -91.3M | -90.8M | -154M | -63.8M | -63.3M | -28.0M | -41.0M | -54.9M |
| EBITDA | -112M | -62.5M | -85.1M | -86.4M | -86.7M | -151M | -61.0M | -55.4M | -16.7M | -29.2M | -49.1M |
| Net Income | -112M | -64.3M | -91.3M | -94.9M | -94.3M | -158M | -67.2M | -66.1M | -39.1M | -61.6M | -73.4M |
| EPS | -2.80 | -1.36 | -1.62 | -1.47 | -1.05 | -1.52 | -0.42 | -0.30 | -0.17 | -0.26 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 213M | 158M | 183M | 260M | 202M | 150M | 190M | 298M | 436M | 502M | 588M |
| Total Liabilities | 20.0M | 18.6M | 67.5M | 73.1M | 75.5M | 67.3M | 91.7M | 131M | 262M | 335M | 423M |
| Shareholders' Equity | 193M | 139M | 116M | 187M | 126M | 82.6M | 98.3M | 167M | 173M | 167M | 164M |
| Cash & Short-term Investments | 201M | 134M | 168M | 248M | 186M | 117M | 124M | 184M | 250M | 265M | 285M |
| Total Debt | - | - | 49.8M | 57.3M | 55.4M | 45.5M | 36.5M | 56.0M | 153M | 212M | 256M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -92.5M | -65.2M | -70.3M | -76.5M | -81.4M | -153M | -70.0M | -89.7M | -44.8M | -42.5M | -48.6M |
| Capital Expenditure | 4.87M | 2.36M | 311K | 325K | 324K | 1.87M | 55.0K | 344K | 1.01M | 1.49M | 109K |
| Free Cash Flow | -97.4M | -67.5M | -70.6M | -76.8M | -81.8M | -154M | -70.1M | -90.1M | -45.8M | -44.0M | -48.7M |
| Ratios | |||||||||||
| ROE | -58.2% | -46.2% | -78.8% | -50.9% | -74.8% | -191.4% | -68.3% | -39.6% | -22.6% | -36.9% | -44.8% |
| ROA | -52.7% | -40.7% | -49.8% | -36.5% | -46.8% | -105.5% | -35.4% | -22.2% | -9.0% | -12.3% | -12.5% |
| Net Profit Margin | -467.8% | -153.2% | -3,502.0% | -1,797.8% | -1,245.7% | -1,566.5% | -128.9% | -53.1% | -11.7% | -15.1% | -16.1% |
| Debt to Equity | - | - | 0.43x | 0.31x | 0.44x | 0.55x | 0.37x | 0.34x | 0.89x | 1.27x | 1.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ardelyx Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 25.9M | 0.12 | - |
| 2022 | - | - | - |
| 2021 | USD 106K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jul 20, 2021.
Who owns Ardelyx Inc
- Insiders 3.72%
- Institutions 71.68%
- Public & others 24.60%
- Shares outstanding 251M
- Free float 213M
Top funds holding ARDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 7.80M | 3.10% | +2.69% | Oct 2026 |
| Nomura Small Cap Core I | 7.63M | 3.04% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 7.40M | 2.95% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 6.13M | 2.44% | 0.00% | Oct 2026 |
| Invesco Biotechnology & Genome ETF | 3.07M | 1.22% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 2.70M | 1.07% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 2.67M | 1.06% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 2.28M | 0.91% | -0.38% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.88M | 0.75% | +9.37% | Sep 2026 |
| Vanguard Explorer Inv | 1.51M | 0.60% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.42M | 0.57% | +1.23% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.34M | 0.53% | +0.24% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.19M | 0.47% | 0.00% | Aug 2026 |
| International Biotechnology Ord | 1.16M | 0.46% | 0.00% | Jul 2026 |
| Fidelity Extended Market Index | 968K | 0.39% | -20.61% | Sep 2026 |
| Nuveen Quant Small/Mid Cap Eq R6 | 921K | 0.37% | 0.00% | Aug 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 782K | 0.31% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 747K | 0.30% | 0.00% | Aug 2026 |
| Vanguard Health Care ETF | 724K | 0.29% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 593K | 0.24% | -0.13% | Sep 2026 |
Top institutions holding ARDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 23.5M | 9.35% | +11.06% | Jun 2026 |
| Rubric Capital Management LP | 16.2M | 6.45% | +770.69% | Jun 2026 |
| Millennium Management LLC | 13.9M | 5.53% | -22.09% | Jun 2026 |
| State Street Corp | 13.4M | 5.31% | -1.82% | Jun 2026 |
| Vanguard Capital Management, LLC | 10.5M | 4.17% | +1.02% | Jun 2026 |
| Delaware Management Holdings Inc | 9.55M | 3.80% | +16.86% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.03M | 3.19% | +20.49% | Jun 2026 |
| Geode Capital Management, LLC | 6.40M | 2.55% | +6.56% | Jun 2026 |
| Jupiter Topco LLC | 5.30M | 2.11% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 5.21M | 2.07% | +21.89% | Jun 2026 |
| Nuveen, LLC | 4.00M | 1.59% | -23.64% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.69M | 1.47% | +14.58% | Jun 2026 |
| AIGH Capital Management, LLC | 3.20M | 1.27% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.39M | 0.95% | +39.82% | Jun 2026 |
| AQR Capital Management LLC | 2.32M | 0.92% | -5.05% | Jun 2026 |
| Northern Trust Corp | 2.28M | 0.91% | +10.10% | Jun 2026 |
| Rock Springs Capital Management LP | 2.24M | 0.89% | -2.51% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.21M | 0.88% | +4.62% | Jun 2026 |
| Bank of America Corp | 2.16M | 0.86% | -7.42% | Jun 2026 |
| Qube Research & Technologies | 2.09M | 0.83% | -14.16% | Jun 2026 |
Ardelyx Inc company profile
- Company name
- Ardelyx Inc
- Ticker
- ARDX.US
- Exchange
- USA Stocks
- Listed since
- Jun 19, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 489
- Fiscal year end
- December
- Address
- 400 Fifth Avenue, Waltham, MA, United States, 02451
- Phone
- 617 675 2739
- Website
- ardelyx.com
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx Inc management
10- Mr. Michael G. RaabPresident, CEO & Director · born 1965
- Ms. Sue HohenleitnerChief Financial Officer · born 1971
- Dr. John Bishop Ph.D.Chief Technical & Quality Officer · born 1962
- Mr. Joseph ReillySenior VP of Finance & Principal Accounting Officer · born 1974
- Ms. Lisa M. CaperelliSenior Vice President of Investor Relations and Corporate Communications
- Ms. Felecia W. EttenbergChief Legal Officer · born 1971
- Mr. James P. BradyChief Human Resources Officer · born 1971
- Dr. Laura A. Williams M.D., M.P.H.Chief Patient Officer Emeritus · born 1963
- Mr. Mike KelliherChief Business Officer · born 1977
- Dr. Rajani Dinavahi M.D.Chief Medical Officer · born 1976